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s  u  m  m  a  r  y
We  report  on a 25-year-old  female  heart  transplant  patient  who  presented  with  recurrent  episodes  of
cellular rejection  due  to  decreased  adherence  to  immunosuppressive  therapy.  She  received  a heart  trans-
plantation in  1994  when  she  was  10  years  old.  In  order  to improve  her adherence  to  immunosuppressive
therapy, switching  to  the  once-daily  extended-release  formulation  of  tacrolimus  was  performed  in  a
step-wise fashion.  First,  the  twice-daily  formulation  of cyclosporin  A  was  replaced  with  the  twice-daily
preparation of  tacrolimus.  When  the trough  blood  levels  of  tacrolimus  reached  a  plateau  in the  range  of
5.0 ng/mL,  it was  changed  to the  once-daily  extended-release  formulation  of  tacrolimus  after  conﬁrming
the absence  of new  rejection  episodes.  There  were  no  signiﬁcant  changes  in  renal  function  before  and
after the  switch.  After  being  discharged  from  the hospital,  the patient  made  signiﬁcant  advancements
in adherence  to  immunosuppressive  therapy.  Her  subsequent  clinical  course  was  uneventful,  with  no
adverse events  observed.  Most  patients  who  undergo  solid  organ  transplantation  must  receive  lifelong
immunosuppressive therapy.  This  case  demonstrates  that  conversion  to the  extended-release  formula-
tion of tacrolimus  from  other  calcineurin  inhibitor  preparations  is  a reasonable  choice  to consider  in the
management of  compromised  immunosuppressive  therapy  adherence  in  heart  transplant  patients  during
the late posttransplant  period.
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For most patients who undergo solid organ transplantation,
trict adherence to immunosuppressive therapy is important for
aintaining  optimal post-transplant immunosuppression.
Extended-release formulation of tacrolimus (Tac-ER) is a once-
aily  oral formulation of tacrolimus (Tac). Previous studies in
idney  and liver transplant patients have demonstrated favor-
ble  rates not only in incidences of biopsy-proven rejections
ut  safety proﬁles [1]. The modiﬁed formulation and the con-
entional  twice-daily Tac show similar exposures as estimated
y  areas under the curve (AUC) and trough levels [minimum
oncentration (Cmin)], with a reduced peak maximum concen-
ration  (Cmax). However, data are limited in heart transplant
atients. Doesch et al. recently reported a signiﬁcant improvement
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n adherence in heart transplant patients after a switch from twice-
aily  calcineurin inhibitor to once-daily Tac-ER [2].
We  report the case of a Japanese heart transplant patient who
resented  with recurrent episodes of cellular rejection due to
ecreased  adherence to immunosuppressive therapy. Replacing
he  twice-daily oral formulation of the calcineurin inhibitor Tac
ith  once-daily Tac-ER achieved stable therapeutic blood levels
nd  helped prevent the recurrent episodes of rejection.
ase report
A  25-year-old woman with a history of dilated cardiomyopathy
tatus post-heart transplantation in 1994 presented with exer-
ional  dyspnea and bilateral pedal edema in 2009. She experienced
pisodes  of moderate cellular rejection for which she received
teroid  pulse therapy in November, 1994, ﬁve months after the
ransplantation. During the following nine years, that is, from
ge  11 to 19 years, her clinical course was uneventful without
ny  episodes of signiﬁcant rejection by the administration of
yclosporine  A (CyA), azathioprine, and low-dose prednisolone.
er  coronary angiography which had been annually performed
vier Ltd. All rights reserved.
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wigure 1. Timeline of the patient’s clinical course before the admission. DCM, dilat
MF,  mycophenolate mofetil; MPA, mycophenolic acid; PSL, prednisolone.
ad showed neither signiﬁcant stenosis nor occlusion. However,
n  the four-year period beginning in 2004, she was  hospitalized six
imes due to acute rejection which needed treatment with intra-
enous  methylprednisolone. Measurements taken during those
ospitalizations showed that the trough levels of CyA were in the
ange of 40–60 ng/mL, considerably lower than the target trough
evel  of 150 ng/mL at that time. The major socio-psychological
vents the patient experienced in the period from 1995 to 2004
age  11–20 years) included a change in her family structure with
er  parents’ divorce. Since becoming a legal adult in 2004, she was
mployed in a series of part-time jobs at night to support living
y  herself and experienced associated changes in her peer rela-
ionships.  Moreover, she went through an emotionally unstable
eriod  in 2005. These events contributed to her non-adherence to
mmunosuppressive therapy.
The  patient began to manifest pedal edema in early March 2009,
ith  increases of her cardiothoracic ratio (64.5%) in her chest X-ray
lm. Her echocardiogram showed the appearance of interventricu-
ar  septal paradoxical motion, increased to moderate from mild tri-
uspid valve regurgitation, increased diameter of inferior vena cava
rom 8.5 mm to 12.1 mm,  and the appearance of mild pericardial
r
r
s
igure 2. Changes in tacrolimus dosage and trough level in Prograf®-based regimen to tac
hite  blood cell; RBC, red blood cell; Hb, hemoglobin; Ht, hematocrit.diomyopathy; HTx, heart transplantation; CyA, cyclosporine A; AZA, azathioprine;
ffusion.  Her laboratory data showed elevated cardiac troponin
 (0.15 ng/mL) and serum N-terminal pro-B-type natriuretic pep-
ide  (NT-proBNP), 4481 pg/mL. She was admitted to our hospital on
arch 17, 2009 for treatment of congestive heart failure. Although
ndomyocardial biopsy at this admission was not performed, the
ow concentration of CyA measured before admission (50 ng/mL)
uggested  that rejection resulting from insufﬁcient immunosup-
ression was at least partially responsible for the onset of her
urrent  cardiac disease (Fig. 1). Her physical ﬁndings at admission
howed  mildly tachycardic (104 beats/min), regular rhythm and
er blood pressure was 98/50 mmHg. She had a third heart sound
nd  exhibited bilateral pedal edema. Laboratory ﬁndings revealed
ild  hepatic congestion (aspartate aminotransferase 57 IU/L;
lanine  aminotransferase 82 IU/L), mild kidney dysfunction
urea nitrogen 31.1 mg/dL; creatinine 1.01 mg/dL; 24-h creatinine
learance  42.2 mL/min).
After her admission, the blood CyA level was  managed so as to
each  the target level of 150 ng/mL.
Her previous history of repeated hospital admissions due to
ejection  episodes resulting from non-compliance to immuno-
uppressive therapy strongly suggested that the patient’s current
rolimus extended-release formulation. Complete blood counts are indicated. WBC,
e28 S. Nunoda et al. / Journal of Cardiol
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iigure 3. Plot of tacrolimus blood concentration under the administration of 2.0 mg
aily tacrolimus extended-release formulation of this case.
ospitalization also involved forgetfulness and carelessness in
aking medications as prescribed. She had received not only CyA
ut  mycophenolate mofetil (MMF)  and the trough level of her
ycophenolic acid had always been between 2 and 4 ng/mL which
as  her target blood level (Fig. 1). The main reason for many
pisodes of her rejection was thought to be due to non-adherence
f  taking calcineurin inhibitor. In order to improve the patient’s
dherence to immunosuppressive therapy, we decided to switch to
he once-daily extended-release formulation of Tac in a step-wise
ashion.  First, the twice-daily formulation of CyA was  replaced
ith  the twice-daily preparation of Tac (Prograf®, Astellas Pharma,
okyo,  Japan). When the Tac (Prograf®) blood levels reached
 plateau in the range of 4.0–5.0 ng/mL, it was changed to the
nce-daily extended-release formulation of Tac (Tac-ER) after
onﬁrming  the absence of new rejection episodes. Four weeks
fter  this switch, dosages were modiﬁed to maintain Tac trough
evels  at the minimum target concentration of 4 ng/mL (Fig. 2). The
atient’s complete blood counts during the conversion had not
hown  signiﬁcant changes (Fig. 2), and the same dosage of MMF
750  mg  bid) and prednisolone (2.5 mg  qd) had been maintained.
er  echocardiography, electrocardiogram, and laboratory ﬁndings
ere  weekly examined during this period, and no occurrence of
ejection was detected.
When  trough levels became stable, pharmacokinetic measure-
ents  were performed. When compared to previously reported
UC  plots for Tac-ER [3], the patient’s AUC plot was similar (Fig. 3).
After the start of the in-hospital treatment, the patient’s bilat-
ral  pedal edema improved. Her clinical course was  uneventful
fter  the change to the Tac-ER formulation. After the treatment,
er  cardiothoracic ratio on chest X-ray ﬁlm decreased to 57.6%,
aradoxical  motion of interventricular septum and pericardial
ffusion on her echocardiogram disappeared, cardiac troponin I
ecreased to 0.03 ng/mL, and NT-proBNP decreased to 742 pg/mL.
here  were no signiﬁcant changes in renal function before and
fter  the switch to the Tac-ER; 24-h creatinine clearance was  in
he range of 42–51 mL/min, and cystatin C levels were in the
ange  of 1.21–1.34 mg/L throughout the conversion to the once-
aily  formulation. After being discharged from the hospital, the
atient  made signiﬁcant advancements in adherence to immuno-
uppressive therapy; the frequency of forgetting to take medication
ecreased  and the compliance to the timing of taking medication
mproved. In outpatient clinic follow-up, the patient did not require
hanges  in the dosing regimen. Her subsequent clinical course was
neventful, with no adverse events observed.iscussion
Tac-ER is a once-daily formulation developed to reduce the fre-
uency  of administration for patients currently using a twice-a-day
M
l
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ac.  For a given dose of Tac, the 24-h AUC values for the twice-daily
tandard-release formulation and the once-daily extended-release
ormulation are similar [4]. In kidney transplant recipients, AUC0–24
as highly correlated to trough level of standard-release formu-
ation  and the once-daily extended-release formulation [1,4]. The
tandard-release formulation has a bimodal concentration–time
roﬁle with a higher maximum concentration (Cmax) than that of
he  extended-release formulation, whereas the extended-release
ormulation has a more gradually tapering proﬁle [1,4].
In  a study by Weng et al., when once-daily was compared to
wice-daily  dosing, a once-daily dosing regimen was found to be
igniﬁcantly associated with higher adherence rates (odds ratio:
.35,  p = 0.003) [5].
According to Denhaerynck et al., patient-related risk factors for
on-adherence  include (i) low self-efﬁcacy with medication taking,
ii) age 20 years and younger, (iii) a long period since the transplan-
ation,  (iv) pre-transplant history of missed clinic visits, (v) mental
r  psychological problems, (vi) social isolation and lack of a social
upport  network, and (vii) substance abuse [6].
During the four-year period in which the patient had recurrent
cute  rejection episodes, her blood CyA concentrations were as
ow as 40–60 ng/mL. The subtherapeutic CyA levels may  be asso-
iated  with the change in her family structure by divorce and
er  leaving home to live an adult life alone in March 2004. To
upport  herself, she was employed in a number of part-time jobs
t  night, which initiated a shift in her peer relationships. Conse-
uently,  she passed a psychologically perturbed period in 2005.
he  patient’s history indicates she exhibited risk factors (i), (iii),
v),  and (vi) listed above. We  concluded that these risk factors
ere  involved in her inadvertently forgetting to take immuno-
uppressive medications on time or at all and immunosuppressive
herapy non-adherence caused the recurrence of acute rejection
pisodes.
Heart  transplant patients who  are compliant with immuno-
uppressive therapy have a signiﬁcantly longer clinical-event-free
eriod (i.e. time to occurrence of late acute rejection, cardiac allo-
raft vasculopathy, retransplantation, and death), when compared
o  immunosuppressive therapy non-compliant patients (p = 0.043)
7]. For renal transplant recipients, Gaston et al. reported that 35%
f late renal allograft losses were associated with immunosup-
ressive therapy non-adherence [8]. Vlaminck et al. reported that
on-compliance in renal transplant patients more than one year
ost-transplant is associated with an increased risk for late acute
ejection  during the following ﬁve years and they concluded that
on-compliance is the most important risk factor in the occurrence
f  late acute rejection [9].
Under  these circumstances, we  prescribed Tac-ER for this
atient  in order to promote immunosuppressive therapy adher-
nce  and thereby maintain a therapeutic blood concentration. To
he best knowledge of the authors, there have been few previ-
usly  reported cases regarding the use of the Tac-ER formulation
n  heart transplant recipients [2]. In renal transplant recipients,
owever, a high correlation between 24-h AUC and trough val-
es  was observed for both the standard-release formulation and
he extended-release formulation [4]. In addition, clinically sta-
le  kidney transplant recipients who switched from standard
o  Tac-ER had stable trough and dosage levels two years post-
onversion. The incidence of biopsy-conﬁrmed acute rejection
6.0%)  and multiple rejections (1.5%) were similar to those for the
wice-daily formulation [1]. Silva et al. also reported that Tac-ER
n  combination with MMF  was noninferior to cyclosporine with
MF  [10].
In  the case reported here, the post-conversion target trough
evels  were satisfactorily maintained. We succeeded in main-
aining  the same outpatient Tac dose by improving the patient’s
ardiol
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e
a
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mmunosuppressive therapy compliance and preventing further
pisodes  of rejection. Moreover, no renal impairment or other
dverse  events were observed before and after the conversion.
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